John J Erickson

US Patent:

7151163, Dec 19, 2006

Filed:

Apr 28, 2004

Appl. No.:

10/833304

Inventors:

John W. Erickson - Potomac MD, US
Abelardo Silva - Ellicott City MD, US

Assignee:

Sequoia Pharmaceuticals, Inc. - Gaithersburg MD

International Classification:

C07K 14/165
C07K 17/00
A61K 39/215
A61K 39/385

US Classification:

530363, 514 12, 4241861, 42419611, 4242211, 4241921

Abstract:

The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infection, in a subject, such as a human subject.

US Patent:

7285566, Oct 23, 2007

Filed:

Jan 7, 2003

Appl. No.:

10/500888

Inventors:

John W. Erickson - Potomac MD, US
Michael Eissenstat - Frederick MD, US
Abelardo Silva - Ellicott City MD, US
Sergei Gulnik - Frederick MD, US

International Classification:

A61K 31/404
C07D 209/30

US Classification:

514367, 514375, 548159, 548222

Abstract:

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

US Patent:

7739671, Jun 15, 2010

Filed:

Aug 12, 2005

Appl. No.:

11/203590

Inventors:

Michael G. Hinchey - Bowie MD, US
James L. Rash - Davidsonville MD, US
John D. Erickson - Midland TX, US
Denis Gracinin - Blacksburg VA, US
Christopher A. Rouff - Beltsville MD, US

Assignee:

The United States of America as represented by the Administrator of the National Aeronautics and Space Administration - Washington DC

International Classification:

G06F 9/44
G06F 9/45
G06F 17/00
G06N 5/04
G06N 5/02

US Classification:

717136, 717117, 717106, 717146, 706922, 706 56, 706 60, 706 46, 706 47

Abstract:

Systems, methods and apparatus are provided through which in some embodiments an informal specification is translated without human intervention into a formal specification. In some embodiments the formal specification is a process-based specification. In some embodiments, the formal specification is translated into a high-level computer programming language which is further compiled into a set of executable computer instructions.

US Patent:

7752608, Jul 6, 2010

Filed:

Aug 12, 2005

Appl. No.:

11/203586

Inventors:

Michael G. Hinchey - Bowie MD, US
James L. Rash - Davidsonville MD, US
John D. Erickson - Midland TX, US
Denis Gracinin - Blacksburg VA, US
Christopher A. Rouff - Beltsville MD, US

Assignee:

The United States of America as represented by the Administrator of the National Aeronautics and Space Administration - Washington DC

International Classification:

G06F 9/45
G06F 9/44
G06F 17/00
G06N 5/04
G06N 5/02

US Classification:

717136, 717107, 717146, 717106, 717117, 706 56, 706 60, 706 46, 706 47

Abstract:

Systems, methods and apparatus are provided through which in some embodiments, domain knowledge is translated into a knowledge-based system. In some embodiments, a formal specification is derived from rules of a knowledge-based system, the formal specification is analyzed, and flaws in the formal specification are used to identify and correct errors in the domain knowledge, from which a knowledge-based system is translated.

US Patent:

20070185027, Aug 9, 2007

Filed:

Nov 9, 2006

Appl. No.:

11/557983

Inventors:

John Erickson - Potomac MD, US
Abelardo Silva - Ellicott City MD, US

Assignee:

SEQUOIA PHARMACEUTICALS, INC. - GAITHERSBURG MD

International Classification:

A61K 38/16
A61K 38/10
A61K 38/08
C07K 7/08
C07K 7/06
C07K 14/165

US Classification:

514012000, 530324000, 530325000, 530326000, 530327000, 530328000, 530329000, 530330000, 514013000, 514014000, 514015000, 514016000, 514017000

Abstract:

The invention provides compositions and methods that are useful for preventing and treating a coronavirus infection in a subject. More specifically, the invention provides peptides and conjugates and pharmaceutical compositions containing those peptides and conjugates that block fusion of a coronavirus, such as the SARS virus, to a target cell. This blocking mechanism prevents or treats a coronavirus infection, such as a SARS infaction, in a subject, such as a human subject.

US Patent:

20070207952, Sep 6, 2007

Filed:

Mar 24, 2004

Appl. No.:

10/550715

Inventors:

Abelardo Silva - Ellicott City MD, US
John Erickson - Potomac MD, US
Michael Eissenstat - Frederick MD, US
Elena Afonina - Frederick MD, US
Sergei Gulnik - Frederick MD, US

Assignee:

SEQUOIA PHARMACEUTICALS - Gaithersburg MD

International Classification:

A61K 38/16
A61K 38/10
C07K 14/47
C07K 7/08

US Classification:

514012000, 530326000, 530324000, 530325000, 514013000, 424078270

Abstract:

The invention provides biologically active compounds that may be reacted with macromolecules, such as albumin, to form covalent linked complexes wherein the resulting complexes exhibit a desired biological activity in vivo. More specifically, the complexes are isolated complexes comprising a biologically active moiety covalently bound to a linking group and a protein. The complexes are prepared by conjugating a biologically active moiety, for example, a renin inhibitor or a viral fusion inhibitor peptide, with purified and isolated protein. The complexes have extended lifetimes in the bloodstream as compared to the unconjugated molecule, and exhibit biological activity for extended periods of time as compared to the unconjugated molecule. The invention also provides anti-viral compounds that are inhibitors of viral infection and/or exhibit anti-fusiogenic properties. In particular, this invention provides compounds having inhibiting activity against viruses such as human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) and that have extended duration of action for the treatment of viral infections.

US Patent:

20100009935, Jan 14, 2010

Filed:

Jul 16, 2009

Appl. No.:

12/504277

Inventors:

John W. Erickson - Potomac MD, US
Michael Eissenstat - Frederick MD, US
Abelardo Silva - Ellicott City MD, US
Sergei Gulnik - Frederick MD, US

Assignee:

SEQUOIA PHARMACEUTICALS - Gaithersburg MD

International Classification:

A61K 31/675
C07D 493/04
C07D 293/10
C07D 307/87
C07D 277/62
C07D 209/04
C07D 311/04
A61K 31/34
A61K 31/36
A61K 31/352
A61K 31/403
A61K 31/428
A61P 31/12

US Classification:

514 80, 549464, 544 1, 549462, 548152, 548452, 549396, 514469, 514464, 514456, 514412, 514367

Abstract:

Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

US Patent:

20180256534, Sep 13, 2018

Filed:

Mar 5, 2018

Appl. No.:

15/912131

Inventors:

- Potomac MD, US
John W. ERICKSON - Potomac MD, US

International Classification:

A61K 31/343
A61K 31/135
A61P 25/24

Abstract:

Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided.Compositions and methods of treating depression infections are provided. More particularly, compositions including a combination of ketamine and a cytochrome p450 enzyme inhibitor are provided. Methods of using the compositions for treatment of depression, including treatment-resistant or treatment-refractory depression, are provided.